Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Sinecatechins

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Sinecatechins used for?
The FDA-approved label (Veregen, ANI Pharmaceuticals, Inc., November 10, 2022) says: “Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. Limitations of Use Safety and effectiveness of Veregen have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Sinecatechins have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Sinecatechins?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Sinecatechins been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Sinecatechins?
1 company lists prescription products of Sinecatechins in the FDA NDC Directory, including ANI Pharmaceuticals, Inc..

What Sinecatechins is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. Limitations of Use Safety and effectiveness of Veregen have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses. …

— FDA label: Veregen, ANI Pharmaceuticals, Inc., effective November 10, 2022. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Forms and how it is given

Dosage formsOintment
RouteTopical
Prescription products1 in the FDA NDC Directory
Brand namesVeregen

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Sinecatechins, by strength and form
Strength and formGeneric or brandPharmacies pay
sinecatechins 15%
ointment
Brand: Veregen $50.85 per gram

NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA021902
VEREGEN
Ani PharmsOctober 31, 2006 12, latest December 19, 2018
2018: Labeling · 2016: Manufacturing (CMC) · 2015: Manufacturing (CMC)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)753350, 795918
SPL set ID of the quoted labelf0fc1e21-e3cf-4bce-860c-307f670b192e
FDA labels (SPL)1
FDA applicationsNDA021902
Active ingredients (FDA)SINECATECHINS

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Veregen, ANI Pharmaceuticals, Inc., effective November 10, 2022; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers